Long End of the Stick

Sustainable and increasingly focused, mid-sized vaccines companies are leading the way in European biotech, catalyzed by fears of bioterrorism and a re-emerging belief that prevention trumps cure, both practically and pharmaco-economically.

As many biotechnology companies struggle to progress pipelines and deal with product setbacks in the face of dwindling cash reserves, Europe's vaccines plays are navigating today's difficult waters more successfully.

Vaccine companies, the perennial middle child of the life sciences, have increased margins on their products, consolidated effectively, jettisoned dead...

In Vivo Podcast

Candid conversations with C-suite leaders.

Keep up with strategy, innovation and evolving trends across life science industries.

More from Deal-Making

More from In Vivo